COMPOUNDS POSSESSING ACIVATING ACTION ON PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SUBTYPES (PPARs), AND METHOD FOR PRODUCING AND USING ABOVE COMPOUNDS
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to a compound of formula (I) or its pharmaceutically acceptable salts of formula (I), wherein X represents O, S； Y represents O, S； R1 independently represents H, alkyl； G1 represents ethyl； each G2 and G3 are independently specified in H, alkyl, trifluoromethyl, halogen, nitro, amido, cyano and tetrazolyl. The invention also refers to a pharmaceutical composition possessing activating action on peroxisome proliferator activated receptors subtype α, subtype δ and subtype γ and containing an effective amount of the compound of formula (I) or its pharmaceutically acceptable salts. The compounds of formula (I) are applicable for treating or producing a drug preparation for treating or preventing the diseases associated with peroxisome proliferator activated receptors subtype α, subtype δ and subtype γ. The compounds of formula (I) are produced by a reaction of the compound of formula (III) and the compound of formula (IV) when heated in acetonitrile under reflux in the presence of potassium carbonate to produce the compound of formula (II), to saponify the compound of formula (II) in alcoholic solution in the presence of alkali and to acidify the reaction mixture to produce the compound of formula (I). X, Y, R1, G1, G2 and G3 have the above values； R3 represents a leaving group specified in OH, Cl, Br, I, OTs, OMs.EFFECT: compounds of phenylpropionic acid possessing the activating action on peroxisome proliferator activated receptors (PPARα, δ, γ).15 cl, 2 exГруппа изобретений относится к соединению формулы (I) или его фармацевтически приемлемым солям формулы (I), где X представляет собой О, S； Υ представляет собой О, S； R1 независимо представляет собой Н, алкил； G1 представляет собой этил； G2 и G3 каждый независимо выбраны из Н, алкила, трифторметила, галогена, нитро, амидо, циано и тетразолила. Также изобретение относится к фармацевтической композиции, обладающей активирующим действием на α-подтип,
